Biomet Announces Agreement With Kensey Nash, Dental Technology, Lawsuit Ruling
July 28, 2016 at 4:25 p.m.
By -
OrthoFill is a unique implant manufactured from Kensey Nash's proprietary Porous Tissue Matrix Technology, which creates foamed scaffolds suited for tissue engineering applications. The OrthoFill product utilizes several resorbable biomaterials including a proprietary collagen formulation, synthetic polymer and ceramic. This unique design creates a structure that is optimized for specific types of bone void filling indications.
Further, OrthoFill utilizes a material composite similar to Kensey Nash's proprietary tissue engineering implant designed to repair damaged articular cartilage in the knee and other articulating joints, currently being evaluated in pre-clinical research. Biomet Sports Medicine and Kensey Nash have agreed to work together to advance the research and development of Kensey Nash's cartilage repair matrix, and will cooperate in future pre-clinical studies.
Surgeons in the United States perform more than 500,000 procedures annually to repair damaged cartilage in the knee. Unlike other tissue types, cartilage possesses a limited capacity to heal.
David A. Nolan, Jr., president of Biomet Sports Medicine, said, "We are pleased to announce our exclusive agreement with Kensey Nash to market and distribute their proprietary OrthoFill Bone Void Filler. They are well known as an innovative pioneer in the field of biomaterials. Additionally, we look forward to partnering in the advancement of research for Kensey Nash's cartilage repair matrix to produce an improved clinical solution for articular cartilage defects."
"As a well-established company, Biomet will be an excellent partner for marketing and distributing our OrthoFill Bone Void Filler," said Joseph W. Kaufmann, president and CEO of Kensey Nash Corp. "We look forward to utilizing our unique biomaterial technologies in future collaborative efforts with Biomet for creating a sophisticated articular cartilage repair product."
Dental technology introduced
Biomet Inc. recently announced that Biomet 3i, the company's dental reconstructive device subsidiary, has introduced a new dental implant that utilizes nanotechnology. The NanoTite Implant builds upon the benefits of Biomet 3i's OSSEOTITE Implant by adding deposits of nano-scale calcium phosphate crystals to approximately 50 percent of the surface. According to pre-clinical studies, these nano-scale deposits create a complex surface on the implant that appears to play a key role in how the implant bonds with the bone. Human bone recognizes calcium phosphate as biologically natural, allowing the bone and implant to bond during healing.
Steven F. Schiess, president of Biomet 3i, said, "The new NanoTite Implant represents a notable advancement in dental implant technology and we are pleased to announce its introduction to the market today."
Dental implants replace single or multiple missing teeth due to cavities, decay, trauma or disease and are designed to help preserve bone structure and natural facial contours. The 2007 dental reconstructive device market is estimated to be approximately $625 million in the United States and exceeds $2 billion worldwide, growing at an annual rate of 15-17 percent.
Ruling in lawsuit
Biomet Inc. recently reported on a ruling issued this week by the United States Court of Appeals for the Federal Circuit in the ongoing patent infringement litigation between Cross Medical Products Inc. (a Biomet subsidiary), Medtronic Sofamor Danek Inc. and Medtronic Sofamor Danek USA Inc.
The Federal Circuit vacated a summary judgment ruling previously issued in Medtronic's favor by the United States District Court for the Central District of California. The district court had ruled that Medtronic's spinal implant polyaxial screws marketed under the names MAS, M8, M10, Sextant, Vertex, Legacy 4.5 and Legacy 5.5 did not infringe claim 7 of Cross's U.S. Patent No. 5,474,555 (the "`555 patent"). In vacating that ruling, the Federal Circuit remanded the matter to the district court for reconsideration. The Federal Circuit also ruled that Medtronic's newly redesigned polyaxial screws do not infringe claims 5 or 7 of the '555 patent. This decision, however, does not impact Medtronic's prior versions of its polyaxial screws.
Biomet's President and Chief Executive Officer Jeffrey R. Binder said, "Although we are disappointed with the Court's decision related to the redesigned polyaxial screws, we are very pleased that the Federal Circuit vacated the district court's prior ruling in favor of Medtronic on the original polyaxial screw designs and we intend to pursue this claim."
A trial on whether Medtronic is liable to Cross for infringement of the '555 patent, and damages owed to Cross on that patent and another spinal patent that the district court already ruled Medtronic has infringed, is expected to take place later this year.[[In-content Ad]]
Latest News
E-Editions
OrthoFill is a unique implant manufactured from Kensey Nash's proprietary Porous Tissue Matrix Technology, which creates foamed scaffolds suited for tissue engineering applications. The OrthoFill product utilizes several resorbable biomaterials including a proprietary collagen formulation, synthetic polymer and ceramic. This unique design creates a structure that is optimized for specific types of bone void filling indications.
Further, OrthoFill utilizes a material composite similar to Kensey Nash's proprietary tissue engineering implant designed to repair damaged articular cartilage in the knee and other articulating joints, currently being evaluated in pre-clinical research. Biomet Sports Medicine and Kensey Nash have agreed to work together to advance the research and development of Kensey Nash's cartilage repair matrix, and will cooperate in future pre-clinical studies.
Surgeons in the United States perform more than 500,000 procedures annually to repair damaged cartilage in the knee. Unlike other tissue types, cartilage possesses a limited capacity to heal.
David A. Nolan, Jr., president of Biomet Sports Medicine, said, "We are pleased to announce our exclusive agreement with Kensey Nash to market and distribute their proprietary OrthoFill Bone Void Filler. They are well known as an innovative pioneer in the field of biomaterials. Additionally, we look forward to partnering in the advancement of research for Kensey Nash's cartilage repair matrix to produce an improved clinical solution for articular cartilage defects."
"As a well-established company, Biomet will be an excellent partner for marketing and distributing our OrthoFill Bone Void Filler," said Joseph W. Kaufmann, president and CEO of Kensey Nash Corp. "We look forward to utilizing our unique biomaterial technologies in future collaborative efforts with Biomet for creating a sophisticated articular cartilage repair product."
Dental technology introduced
Biomet Inc. recently announced that Biomet 3i, the company's dental reconstructive device subsidiary, has introduced a new dental implant that utilizes nanotechnology. The NanoTite Implant builds upon the benefits of Biomet 3i's OSSEOTITE Implant by adding deposits of nano-scale calcium phosphate crystals to approximately 50 percent of the surface. According to pre-clinical studies, these nano-scale deposits create a complex surface on the implant that appears to play a key role in how the implant bonds with the bone. Human bone recognizes calcium phosphate as biologically natural, allowing the bone and implant to bond during healing.
Steven F. Schiess, president of Biomet 3i, said, "The new NanoTite Implant represents a notable advancement in dental implant technology and we are pleased to announce its introduction to the market today."
Dental implants replace single or multiple missing teeth due to cavities, decay, trauma or disease and are designed to help preserve bone structure and natural facial contours. The 2007 dental reconstructive device market is estimated to be approximately $625 million in the United States and exceeds $2 billion worldwide, growing at an annual rate of 15-17 percent.
Ruling in lawsuit
Biomet Inc. recently reported on a ruling issued this week by the United States Court of Appeals for the Federal Circuit in the ongoing patent infringement litigation between Cross Medical Products Inc. (a Biomet subsidiary), Medtronic Sofamor Danek Inc. and Medtronic Sofamor Danek USA Inc.
The Federal Circuit vacated a summary judgment ruling previously issued in Medtronic's favor by the United States District Court for the Central District of California. The district court had ruled that Medtronic's spinal implant polyaxial screws marketed under the names MAS, M8, M10, Sextant, Vertex, Legacy 4.5 and Legacy 5.5 did not infringe claim 7 of Cross's U.S. Patent No. 5,474,555 (the "`555 patent"). In vacating that ruling, the Federal Circuit remanded the matter to the district court for reconsideration. The Federal Circuit also ruled that Medtronic's newly redesigned polyaxial screws do not infringe claims 5 or 7 of the '555 patent. This decision, however, does not impact Medtronic's prior versions of its polyaxial screws.
Biomet's President and Chief Executive Officer Jeffrey R. Binder said, "Although we are disappointed with the Court's decision related to the redesigned polyaxial screws, we are very pleased that the Federal Circuit vacated the district court's prior ruling in favor of Medtronic on the original polyaxial screw designs and we intend to pursue this claim."
A trial on whether Medtronic is liable to Cross for infringement of the '555 patent, and damages owed to Cross on that patent and another spinal patent that the district court already ruled Medtronic has infringed, is expected to take place later this year.[[In-content Ad]]
Have a news tip? Email [email protected] or Call/Text 360-922-3092